IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
7
Bullish
4
Bearish
27
Neutral
15
Bullish
4
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Bearish
24
Neutral
8
Bullish
0
Pharmaceuticals & Biotechnology
Pharmaceuticals
28 Cr
Low Risk
6.8
39.5
—
1.2
60.00
28.13
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
43.12 | 34 Cr | 260.92 | 1.93 | 0.00 | 23.13 | 15.39 | 0.18 | ||
21.39 | 27 Cr | -533.40 | 0.24 | 0.00 | -0.04 | -0.03 | -0.04 | ||
18.20 | 26 Cr | 4.23 | 0.68 | 0.00 | 14.94 | 18.81 | 10.46 | ||
16.80 | 24 Cr | 38.27 | 0.96 | 0.00 | 2.76 | 0.90 | — | ||
0.19 | 23 Cr | -1.38 | 0.24 | 0.00 | -5.66 | -5.66 | -3.33 | ||
4.55 | 23 Cr | -1.38 | 0.46 | 0.00 | -26.30 | -22.21 | -24.96 | ||
| Median: 6 Co. | — | 17.50 | 25 Cr | 1.43 | 0.57 | 0.00 | 1.36 | 0.44 | -0.04 |
Regulatory/Compliance Filing
Goldline Pharmaceutical reported no deviation or variation in the use of ₹10.06 crore of IPO proceeds for the half year ended September 30, 2026.
Financial Results
Goldline Pharmaceutical’s Board approved unaudited standalone financial results for the half year ended September 30, 2026, along with the balance sheet.
Goldline Pharmaceutical Ltd is currently trading at 29.27 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Goldline Pharmaceutical Ltd operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, Goldline Pharmaceutical Ltd has traded between a low of ₹28.13 and a high of ₹60.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Goldline Pharmaceutical Ltd has a market capitalization of approximately 28.10. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Goldline Pharmaceutical Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 6.82 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 28.10 Cr, Goldline Pharmaceutical Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Goldline Pharmaceutical Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Goldline Pharmaceutical Ltd is 6.82. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Goldline Pharmaceutical reported profit after tax of Rs 2.05 crore for the half year ended September 30, 2026. The figure was Rs 1.42 crore for the corresponding half year ended September 30, 2025. Profit after tax was Rs 2.76 crore in the immediately preceding March 2026 half year.
Goldline Pharmaceutical reported Rs 2.70 crore of proceeds from share capital and Rs 8.91 crore from securities premium in the half year ended September 30, 2026. Together, the stated proceeds were Rs 11.61 crore. The cash-flow statement also records Rs 1.76 crore of share-issue expenses.
GLPL's board meeting is scheduled for November 14, 2026. The board will consider standalone unaudited financial results for the half-year ended September 30, 2026, along with a statement of assets and liabilities.
